MARKET

MGTA

MGTA

Magenta Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.44
+0.31
+4.35%
After Hours: 7.44 0 0.00% 16:04 12/04 EST
OPEN
7.25
PREV CLOSE
7.13
HIGH
7.48
LOW
7.21
VOLUME
135.77K
TURNOVER
--
52 WEEK HIGH
16.19
52 WEEK LOW
5.76
MARKET CAP
359.39M
P/E (TTM)
-3.8138
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Zacks.com featured highlights include: Blue Apron Holdings, Magenta Therapeutics, Credit Acceptance Corp, Clean Harbors and LogicBio Therapeutics
Zacks.com featured highlights include: Blue Apron Holdings, Magenta Therapeutics, Credit Acceptance Corp, Clean Harbors and LogicBio Therapeutics
Zacks · 1d ago
Magenta Therapeutics, bluebird bio team up for MGTA-145 combo trial in sickle cell disease
Magenta Therapeutics (MGTA) and bluebird bio (BLUE) have entered into clinical trial collaboration to evaluate MGTA-145, a CXCR2 agonist, in combination with plerixafor, a CXCR4 antagonist, for mobilization and collection of stem cells
Seekingalpha · 1d ago
Magenta Therapeutics And bluebird bio Announce A Phase 2 Clinical Trial Collaboration To Evaluate Magenta's MGTA-145 For Mobilizing And Collecting Stem Cells In Adults And Adolescents With Sickle Cell Disease
Magenta Therapeutics (NASDAQ:MGTA) and bluebird bio, Inc. (NASDAQ:BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization
Benzinga · 1d ago
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta's MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease
Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD). The data from this clinical trial could provide proof-of-concept for MGTA-145, in combination with plerixafor, as the preferred mobilization regimen for patients with SCD. bluebird bio's experience with plerixafor as a mobilization agent in sickle cell disease aligns with Magenta's combination therapy approach, utilizing MGTA-145 plus plerixafor with potential to achieve safe, rapid and reliable mobilization of sufficient quantities of high-quality stem cells to improve outcomes associated with stem cell transplantation. Under the collaboration, the stem cells will be fully characterized, and Magenta will undertake preclinical studies to evaluate the ability of these cells to be gene corrected and engrafted in mouse models. The companies will co-fund the clinical trial and Magenta will retain all rights to its product candidate.
BusinessWire · 1d ago
Bet on 5 Top Stocks With Rising P/E for Spectacular Returns
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
Zacks · 2d ago
The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12)
Benzinga · 11/13 12:40
Hedge Funds Have Never Been This Bullish On Magenta Therapeutics, Inc. (MGTA)
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend
Insider Monkey · 10/07 16:46
AVROBIO's Gaucher Disease Candidate Gets Orphan Drug Status
AVROBIO's (AVRO) gene therapy candidate for Gaucher disease, AVR-RD-02, gets orphan drug designation from the European Commission.
Zacks · 09/29 14:48
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MGTA. Analyze the recent business situations of Magenta Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MGTA stock price target is 16.67 with a high estimate of 22.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 132
Institutional Holdings: 28.84M
% Owned: 59.70%
Shares Outstanding: 48.30M
TypeInstitutionsShares
Increased
34
1.23M
New
34
-1.68M
Decreased
16
549.89K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Michael Bonney
President/Chief Executive Officer/Co-Founder/Director
Jason Gardner
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance
Cindy Driscoll
Chief Human Resource Officer
Kristen Stants
Senior Vice President
Li Malmberg
Other
John Davis
Other
Christina Isacson
Secretary
Zoran Zdraveski
Independent Director
Jeffrey Albers
Independent Director
Bruce Booth
Independent Director
Alexis Borisy
Independent Director
Blake Byers
Independent Director
Thomas Daniel
Independent Director
Anne McGeorge
Independent Director
Amy Ronneberg
Independent Director
David Scadden
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MGTA
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics to transform hematopoietic stem cell transplants for patients with immune and blood-based diseases. It maintains a platform with integrated and modular approach, which aims to reboot the blood and immune systems. The Company’s products include MGTA-145, MGTA-456, E478, and G100. The Company also developing a pipeline of small molecules; biologics, including antibody drug conjugates; and a cell therapy, which transplant options for many more patients with autoimmune diseases, blood cancers and genetic diseases. The Company’s C100 program targets HSCs, immune cells, and disease-causing cells, the C200 program targets HSCs and disease-causing cells and the C300 program targets only immune cells. This is achieved by tuning the antibodies to specific cellular markers or receptors that are expressed on the particular cell types.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Magenta Therapeutics Inc stock information, including NASDAQ:MGTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MGTA stock methods without spending real money on the virtual paper trading platform.